- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- INCA034176, Placebo, Corticosteroids
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Duarte, California + 32 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 457–480
of 3,153
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Mandible Tumor, Mandibular Injuries, Mandible; Deformity
- Interventions
- EB-CMF
- Combination Product
- Lead sponsor
- Epibone, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- San Francisco, California • Cleveland, Ohio • San Antonio, Texas
- Conditions
- Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
- Interventions
- Tazemetostat, Placebo oral tablet, Lenalidomide, Rituximab
- Drug · Combination Product
- Lead sponsor
- Epizyme, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 599 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 57
- States / cities
- Mobile, Alabama • Tucson, Arizona • Cerritos, California + 47 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Adjuvant, Observation
- Drug · Other
- Lead sponsor
- Insight Molecular Diagnostics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 18
- States / cities
- Duarte, California • Washington D.C., District of Columbia • Jupiter, Florida + 13 more
- Conditions
- Spinal Cord Injury
- Interventions
- MT-3921, Placebo
- Biological
- Lead sponsor
- Tanabe Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 15
- States / cities
- Orange, California • Tallahassee, Florida • Augusta, Georgia + 12 more
- Conditions
- Advanced Solid Tumors
- Interventions
- YL211, YL211+Pembrolizumab, YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin)
- Drug
- Lead sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Denver, Colorado • North Haven, Connecticut + 7 more
- Conditions
- Neurotrophic Keratopathy
- Interventions
- OC-01 (varenicline) nasal spray 1.2 mg/ml, Placebo (vehicle) nasal spray
- Drug
- Lead sponsor
- Oyster Point Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 31
- States / cities
- Dothan, Alabama • Irvine, California • Los Angeles, California + 27 more
- Conditions
- Erosive Esophagitis
- Interventions
- Vonoprazan, Lansoprazole
- Drug
- Lead sponsor
- Phathom Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,027 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 109
- States / cities
- Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 88 more
- Conditions
- Type 2 Diabetes, Heart Failure, Reduced Ejection Fraction
- Interventions
- Ketone Monoester (KE)
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Preneoplastic Conditions, Prostatic Intraepithelial Neoplasia
- Interventions
- Toremifene 20 mg, Placebo
- Drug
- Lead sponsor
- GTx
- Industry
- Eligibility
- 30 Years and older · Male only
- Enrollment
- 1,589 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 108
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 93 more
- Conditions
- Advanced Prostate Cancer, Prostatic Neoplasms
- Interventions
- sipuleucel-T
- Biological
- Lead sponsor
- Dendreon
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,976 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 333
- States / cities
- Bessemer, Alabama • Birmingham, Alabama • Huntsville, Alabama + 245 more
- Conditions
- Superficial Bladder Cancer
- Interventions
- ADSTILADRIN
- Biological
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 34
- States / cities
- Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 29 more
- Conditions
- Non-muscle-invasive Bladder Cancer
- Interventions
- STM-416
- Drug
- Lead sponsor
- SURGE Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 20
- States / cities
- Mesa, Arizona • Tucson, Arizona • Little Rock, Arkansas + 16 more
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- TAK-188
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 15
- States / cities
- Santa Monica, California • New Haven, Connecticut • Orlando, Florida + 12 more
- Conditions
- Cardiovascular Disease
- Interventions
- bococizumab (PF-04950615), Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10,564 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 518
- States / cities
- Athens, Alabama • Birmingham, Alabama • Fort Payne, Alabama + 328 more
- Conditions
- Vulvovaginal Atrophy
- Interventions
- WC3011 Estradiol Vaginal Cream
- Drug
- Lead sponsor
- Warner Chilcott
- Industry
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 64
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more
- Conditions
- Leukemia
- Interventions
- filgrastim, cladribine, idarubicin
- Biological · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2007
- U.S. locations
- 206
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
- Conditions
- Bladder Cancer Recurrence
- Interventions
- Not listed
- Lead sponsor
- Predictive Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Engelwood, Colorado • Daytona Beach, Florida + 16 more
- Conditions
- HRAS Gene Mutation, HNSCC
- Interventions
- Tipifarnib, HRAS Detection Assay
- Drug · Device
- Lead sponsor
- Kura Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 29
- States / cities
- Los Angeles, California • San Francisco, California • Whittier, California + 23 more
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Cilofexor, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 419 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 82
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Coronado, California + 65 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Upadacitinib, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 87
- States / cities
- Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 73 more
- Conditions
- Osteoarthritis, Knee
- Interventions
- Pentosan Polysulfate Sodium twice weekly, Placebo (Sodium Chloride Injection, 0.9%), Pentosan Polysulfate Sodium Fixed Dose, Pentosan Polysulfate Sodium once weekly
- Drug
- Lead sponsor
- Paradigm Biopharmaceuticals USA (INC)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 602 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 29
- States / cities
- Tempe, Arizona • Tucson, Arizona • Cerritos, California + 20 more
- Conditions
- Obesity Prevention, Sarcopenia in Elderly, Cardiovascular Function, GLP - 1, Weight Loss
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg, Placebo - 100 mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 16 more